AKTIS ONCOLOGY INC (AKTS) — insider trading
Health Care · NASDAQ
AKTIS ONCOLOGY INC (AKTS) has 63 reported SEC Form 4 insider transactions in our data, including 9 open-market purchases and 6 open-market sales among the most recent 63 (latest 2026-07-08).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-07-08 | Czibere Akos | Officer (Chief Medical Officer) | Option exercise / conversion (derivative) | 50,000 | $0.00 | $0 | Form 4 |
| 2026-07-08 | Czibere Akos | Officer (Chief Medical Officer) | Open-market sale | 4,371 | $28.71 | $125.5K | Form 4 |
| 2026-07-08 | Czibere Akos | Officer (Chief Medical Officer) | Open-market sale | 30,829 | $27.95 | $861.7K | Form 4 |
| 2026-07-08 | Czibere Akos | Officer (Chief Medical Officer) | Open-market sale | 14,800 | $27.13 | $401.5K | Form 4 |
| 2026-07-08 | Czibere Akos | Officer (Chief Medical Officer) | Option exercise / conversion | 50,000 | $4.95 | $247.5K | Form 4 |
| 2026-07-08 | Ron-Bigger Shulamit | Officer (Chief Operating Officer) | Option exercise / conversion (derivative) | 50,000 | $0.00 | $0 | Form 4 |
| 2026-07-08 | Ron-Bigger Shulamit | Officer (Chief Operating Officer) | Open-market sale | 4,200 | $28.75 | $120.7K | Form 4 |
| 2026-07-08 | Ron-Bigger Shulamit | Officer (Chief Operating Officer) | Open-market sale | 30,000 | $27.94 | $838.1K | Form 4 |
| 2026-07-08 | Ron-Bigger Shulamit | Officer (Chief Operating Officer) | Open-market sale | 15,800 | $27.13 | $428.7K | Form 4 |
| 2026-07-08 | Ron-Bigger Shulamit | Officer (Chief Operating Officer) | Option exercise / conversion | 50,000 | $3.66 | $183.0K | Form 4 |
| 2026-04-15 | Gormley Glenn | Director | Grant / award / vesting (derivative) | 37,866 | $0.00 | $0 | Form 4 |
| 2026-01-12 | GADICKE ANSBERT; MPM ASSET MANAGEMENT LLC; Oncology Impact Private Investment Fund 2, L.P. | 10% owner | Conversion of derivative (derivative) | 6,000,000 | $0.00 | $0 | Form 4 |
| 2026-01-12 | GADICKE ANSBERT; MPM ASSET MANAGEMENT LLC; Oncology Impact Private Investment Fund 2, L.P. | 10% owner | Conversion of derivative (derivative) | 22,500,000 | $0.00 | $0 | Form 4 |
| 2026-01-12 | GADICKE ANSBERT; MPM ASSET MANAGEMENT LLC; Oncology Impact Private Investment Fund 2, L.P. | 10% owner | Conversion of derivative (derivative) | 5,000,000 | $0.00 | $0 | Form 4 |
| 2026-01-12 | GADICKE ANSBERT; MPM ASSET MANAGEMENT LLC; Oncology Impact Private Investment Fund 2, L.P. | 10% owner | Open-market purchase | 1,112,777 | $18.00 | $20.03M | Form 4 |
| 2026-01-12 | GADICKE ANSBERT; MPM ASSET MANAGEMENT LLC; Oncology Impact Private Investment Fund 2, L.P. | 10% owner | Conversion of derivative | 1,577,119 | — | — | Form 4 |
| 2026-01-12 | GADICKE ANSBERT; MPM ASSET MANAGEMENT LLC; Oncology Impact Private Investment Fund 2, L.P. | 10% owner | Conversion of derivative | 5,914,197 | — | — | Form 4 |
| 2026-01-12 | GADICKE ANSBERT; MPM ASSET MANAGEMENT LLC; Oncology Impact Private Investment Fund 2, L.P. | 10% owner | Conversion of derivative | 1,314,262 | — | — | Form 4 |
| 2026-01-12 | MPM BIOVENTURES 2018, L.P.; EVNIN LUKE; MPM BIOVENTURES 2018 (B), L.P.; MPM BioVentures 2018 LLC; MPM BioVentures 2018 GP LLC; MPM ASSET MANAGEMENT INVESTORS BV2018 LLC; MPM ONCOLOGY INNOVATIONS FUND LP; MPM Oncology Innovations Fund GP LLC | 10% owner | Conversion of derivative (derivative) | 6,000,000 | $0.00 | $0 | Form 4 |
| 2026-01-12 | MPM BIOVENTURES 2018, L.P.; EVNIN LUKE; MPM BIOVENTURES 2018 (B), L.P.; MPM BioVentures 2018 LLC; MPM BioVentures 2018 GP LLC; MPM ASSET MANAGEMENT INVESTORS BV2018 LLC; MPM ONCOLOGY INNOVATIONS FUND LP; MPM Oncology Innovations Fund GP LLC | 10% owner | Conversion of derivative (derivative) | 22,500,000 | $0.00 | $0 | Form 4 |
| 2026-01-12 | MPM BIOVENTURES 2018, L.P.; EVNIN LUKE; MPM BIOVENTURES 2018 (B), L.P.; MPM BioVentures 2018 LLC; MPM BioVentures 2018 GP LLC; MPM ASSET MANAGEMENT INVESTORS BV2018 LLC; MPM ONCOLOGY INNOVATIONS FUND LP; MPM Oncology Innovations Fund GP LLC | 10% owner | Conversion of derivative (derivative) | 5,000,000 | $0.00 | $0 | Form 4 |
| 2026-01-12 | MPM BIOVENTURES 2018, L.P.; EVNIN LUKE; MPM BIOVENTURES 2018 (B), L.P.; MPM BioVentures 2018 LLC; MPM BioVentures 2018 GP LLC; MPM ASSET MANAGEMENT INVESTORS BV2018 LLC; MPM ONCOLOGY INNOVATIONS FUND LP; MPM Oncology Innovations Fund GP LLC | 10% owner | Open-market purchase | 1,112,777 | $18.00 | $20.03M | Form 4 |
| 2026-01-12 | MPM BIOVENTURES 2018, L.P.; EVNIN LUKE; MPM BIOVENTURES 2018 (B), L.P.; MPM BioVentures 2018 LLC; MPM BioVentures 2018 GP LLC; MPM ASSET MANAGEMENT INVESTORS BV2018 LLC; MPM ONCOLOGY INNOVATIONS FUND LP; MPM Oncology Innovations Fund GP LLC | 10% owner | Conversion of derivative | 1,577,119 | — | — | Form 4 |
| 2026-01-12 | MPM BIOVENTURES 2018, L.P.; EVNIN LUKE; MPM BIOVENTURES 2018 (B), L.P.; MPM BioVentures 2018 LLC; MPM BioVentures 2018 GP LLC; MPM ASSET MANAGEMENT INVESTORS BV2018 LLC; MPM ONCOLOGY INNOVATIONS FUND LP; MPM Oncology Innovations Fund GP LLC | 10% owner | Conversion of derivative | 5,914,197 | — | — | Form 4 |
| 2026-01-12 | MPM BIOVENTURES 2018, L.P.; EVNIN LUKE; MPM BIOVENTURES 2018 (B), L.P.; MPM BioVentures 2018 LLC; MPM BioVentures 2018 GP LLC; MPM ASSET MANAGEMENT INVESTORS BV2018 LLC; MPM ONCOLOGY INNOVATIONS FUND LP; MPM Oncology Innovations Fund GP LLC | 10% owner | Conversion of derivative | 1,314,262 | — | — | Form 4 |
| 2026-01-12 | Foley Todd | Director, 10% owner | Conversion of derivative (derivative) | 2,727,273 | $0.00 | $0 | Form 4 |
| 2026-01-12 | Foley Todd | Director, 10% owner | Conversion of derivative (derivative) | 10,227,273 | $0.00 | $0 | Form 4 |
| 2026-01-12 | Foley Todd | Director, 10% owner | Conversion of derivative (derivative) | 2,272,727 | $0.00 | $0 | Form 4 |
| 2026-01-12 | Foley Todd | Director, 10% owner | Open-market purchase | 232,870 | $18.00 | $4.19M | Form 4 |
| 2026-01-12 | Foley Todd | Director, 10% owner | Conversion of derivative | 716,872 | — | — | Form 4 |
| 2026-01-12 | Foley Todd | Director, 10% owner | Conversion of derivative | 2,688,270 | — | — | Form 4 |
| 2026-01-12 | Foley Todd | Director, 10% owner | Conversion of derivative | 597,391 | — | — | Form 4 |
| 2026-01-12 | Segal Lloyd Mitchell | Director | Conversion of derivative (derivative) | 24,687 | $0.00 | $0 | Form 4 |
| 2026-01-12 | Segal Lloyd Mitchell | Director | Conversion of derivative (derivative) | 50,000 | $0.00 | $0 | Form 4 |
| 2026-01-12 | Segal Lloyd Mitchell | Director | Conversion of derivative | 19,631 | — | — | Form 4 |
| 2026-01-12 | Kim Helen Susan | Director, 10% owner | Conversion of derivative (derivative) | 101,250 | $0.00 | $0 | Form 4 |
| 2026-01-12 | Kim Helen Susan | Director, 10% owner | Conversion of derivative (derivative) | 3,648,750 | $0.00 | $0 | Form 4 |
| 2026-01-12 | Kim Helen Susan | Director, 10% owner | Conversion of derivative (derivative) | 411,750 | $0.00 | $0 | Form 4 |
| 2026-01-12 | Kim Helen Susan | Director, 10% owner | Conversion of derivative (derivative) | 14,838,250 | $0.00 | $0 | Form 4 |
| 2026-01-12 | Kim Helen Susan | Director, 10% owner | Open-market purchase | 22,545 | $18.00 | $405.8K | Form 4 |
| 2026-01-12 | Kim Helen Susan | Director, 10% owner | Conversion of derivative | 134,842 | — | — | Form 4 |
| 2026-01-12 | Kim Helen Susan | Director, 10% owner | Open-market purchase | 812,455 | $18.00 | $14.62M | Form 4 |
| 2026-01-12 | Kim Helen Susan | Director, 10% owner | Conversion of derivative | 4,859,370 | — | — | Form 4 |
| 2026-01-12 | Vida Ventures II, LLC; VIDA VENTURES II-A, LLC | 10% owner | Conversion of derivative (derivative) | 101,250 | $0.00 | $0 | Form 4 |
| 2026-01-12 | Vida Ventures II, LLC; VIDA VENTURES II-A, LLC | 10% owner | Conversion of derivative (derivative) | 3,648,750 | $0.00 | $0 | Form 4 |
| 2026-01-12 | Vida Ventures II, LLC; VIDA VENTURES II-A, LLC | 10% owner | Conversion of derivative (derivative) | 411,750 | $0.00 | $0 | Form 4 |
| 2026-01-12 | Vida Ventures II, LLC; VIDA VENTURES II-A, LLC | 10% owner | Conversion of derivative (derivative) | 14,838,250 | $0.00 | $0 | Form 4 |
| 2026-01-12 | Vida Ventures II, LLC; VIDA VENTURES II-A, LLC | 10% owner | Open-market purchase | 22,545 | $18.00 | $405.8K | Form 4 |
| 2026-01-12 | Vida Ventures II, LLC; VIDA VENTURES II-A, LLC | 10% owner | Conversion of derivative | 134,842 | — | — | Form 4 |
| 2026-01-12 | Vida Ventures II, LLC; VIDA VENTURES II-A, LLC | 10% owner | Open-market purchase | 812,455 | $18.00 | $14.62M | Form 4 |
| 2026-01-12 | Vida Ventures II, LLC; VIDA VENTURES II-A, LLC | 10% owner | Conversion of derivative | 4,859,370 | — | — | Form 4 |
| 2026-01-12 | EcoR1 Capital, LLC; NODELMAN OLEG | Director | Conversion of derivative (derivative) | 86,222 | — | — | Form 4 |
| 2026-01-12 | EcoR1 Capital, LLC; NODELMAN OLEG | Director | Conversion of derivative (derivative) | 965,190 | — | — | Form 4 |
| 2026-01-12 | EcoR1 Capital, LLC; NODELMAN OLEG | Director | Conversion of derivative (derivative) | 102,500 | — | — | Form 4 |
| 2026-01-12 | EcoR1 Capital, LLC; NODELMAN OLEG | Director | Conversion of derivative (derivative) | 2,397,500 | — | — | Form 4 |
| 2026-01-12 | EcoR1 Capital, LLC; NODELMAN OLEG | Director | Conversion of derivative (derivative) | 488,891 | — | — | Form 4 |
| 2026-01-12 | EcoR1 Capital, LLC; NODELMAN OLEG | Director | Conversion of derivative (derivative) | 997,299 | — | — | Form 4 |
| 2026-01-12 | EcoR1 Capital, LLC; NODELMAN OLEG | Director | Conversion of derivative (derivative) | 9,913,810 | — | — | Form 4 |
| 2026-01-12 | EcoR1 Capital, LLC; NODELMAN OLEG | Director | Open-market purchase | 144,443 | $18.00 | $2.60M | Form 4 |
| 2026-01-12 | EcoR1 Capital, LLC; NODELMAN OLEG | Director | Open-market purchase | 2,077,779 | $18.00 | $37.40M | Form 4 |
| 2026-01-12 | EcoR1 Capital, LLC; NODELMAN OLEG | Director | Conversion of derivative | 128,506 | — | — | Form 4 |
| 2026-01-12 | EcoR1 Capital, LLC; NODELMAN OLEG | Director | Conversion of derivative | 202,862 | — | — | Form 4 |
| 2026-01-12 | EcoR1 Capital, LLC; NODELMAN OLEG | Director | Conversion of derivative | 2,270,879 | — | — | Form 4 |
Ask the chat about AKTS's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: AKTIS ONCOLOGY INC (AKTS).
Last updated 2026-07-08 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.